These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 16954326

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 27. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 28. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 29. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.
    Depress Anxiety; 2009 Dec; 26(3):212-21. PubMed ID: 19194995
    [Abstract] [Full Text] [Related]

  • 30. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [Abstract] [Full Text] [Related]

  • 31. Innovations and recent trends in the treatment of ADHD.
    Madaan V, Kinnan S, Daughton J, Kratochvil CJ.
    Expert Rev Neurother; 2006 Sep; 6(9):1375-85. PubMed ID: 17009924
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 33. Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective.
    Babcock T, Ornstein CS.
    Postgrad Med; 2009 May; 121(3):73-82. PubMed ID: 19491543
    [Abstract] [Full Text] [Related]

  • 34. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

  • 35. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
    Sleep Med; 2007 Jan 15; 8(1):18-30. PubMed ID: 17157069
    [Abstract] [Full Text] [Related]

  • 36. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.
    Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ.
    Neuropsychopharmacology; 2004 Jul 15; 29(7):1363-73. PubMed ID: 15085092
    [Abstract] [Full Text] [Related]

  • 37. Modafinil in children with attention-deficit hyperactivity disorder.
    Rugino TA, Samsock TC.
    Pediatr Neurol; 2003 Aug 15; 29(2):136-42. PubMed ID: 14580657
    [Abstract] [Full Text] [Related]

  • 38. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD.
    Arnold VK, Feifel D, Earl CQ, Yang R, Adler LA.
    J Atten Disord; 2014 Feb 15; 18(2):133-44. PubMed ID: 22617860
    [Abstract] [Full Text] [Related]

  • 39. [Modafinil in psychiatric disorders: the promising state reconsidered].
    Joos L, Docx L, Schmaal L, Sabbe BG, Dom G.
    Tijdschr Psychiatr; 2010 Feb 15; 52(11):763-73. PubMed ID: 21064019
    [Abstract] [Full Text] [Related]

  • 40. Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder.
    Flavell J.
    Australas Psychiatry; 2021 Jun 15; 29(3):366-367. PubMed ID: 32713188
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.